Shukra Pharmaceuticals (524632) Q4 12/13 earnings summary

Executive summary

• FY2012-13 revenue declined to ₹51.76m from ₹66.49m; the year ended with a ₹29.31m loss, including substantial extraordinary and prior-period items.

• Operations were described as undergoing restructuring, with turnover improvement as a priority; a revival and amalgamation scheme was pending final hearing.

Financial highlights

• Revenue from operations was ₹51.13m, down from ₹66.33m YoY; total revenue was ₹51.76m versus ₹66.49m.

• Loss before exceptional and extraordinary items and tax was ₹2.20m, versus a ₹1.70m loss in FY2011-12.

• Reported net loss was ₹29.31m versus net income of ₹9.54m; extraordinary items included ₹25.39m income, ₹26.72m in sundry write-offs, ₹1.42m prior-period expense, ₹1.76m suspension-related expense and ₹0.39m fire loss.

• Depreciation rose to ₹7.29m from ₹4.46m; total expenses were ₹53.96m versus ₹68.18m.

Outlook and guidance

• Management said operations were in restructuring and turnover improvement was a focus; no quantified financial guidance was stated.

• Plans included pursuing ISO 9000 certification and advancing a sophisticated injectable plant, alongside continuous improvement and customer-focused growth.